Assoc. Prof. Elif Şenocak Taşçı is a medical oncologist affiliated with Acıbadem Health Group. She completed her medical oncology training at Acıbadem Mehmet Ali Aydınlar University Faculty of Medicine in 2023 and has continued her clinical and academic work within the Acıbadem network since 2025. Known for a patient-centered approach, she combines evidence-based cancer care with clear communication and compassionate support for patients and families. Her interests include delivering personalized treatment plans, participating in multidisciplinary care, and staying current with advances in oncology to improve outcomes and quality of life for those she treats.
Education
- 2023 Acıbadem Mehmet Ali Aydınlar University Faculty of Medicine Medical Oncology
- 2017 Duzce University Faculty of Medicine Internal Medicine
- 2012 Yeditepe University Faculty of Medicine
Experience
- 2025 Acibadem Health Group
- 2023 – 2025 Kanuni Sultan Süleyman Training and Research Hospital / Medical Oncology Specialist
- 2019 – 2020 Haydarpasa Numune Training and Research Hospital / Internal Medicine Specialist
Publications
- A multi-center case-control study on osteoporosis risk in cancer patients receiving chemotherapy.
J Clin Oncol. 2025 ;43(16_suppl): 1203 3. Goktas Aydin S, Aydin A, Demirel BC, et al. - Predicting osteoporosis in elderly cancer patients using the modified Glasgow prognostic index
Cancer Control. 2025;32:10732748251337601. Ustuner M, Goktas Aydin S, Aydin A, et al - Real world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: a Turkish oncology group retrospective study.
Mol Clin Oncol. 2025;22(6):51. Ozgun A, Mustafayev FNA, Dogan I, et al - Assessment of health literacy and HPV knowledge among university students: an observational study
Medicine (Baltimore). 2024; 103(35). Senocak Tasci E, Bas D, Kayak S, et al. - Real-world efficacy and safety of fırst-line nivolumab plus chemotherapy in patients with advanced gastric, gastroesophageal junction, and esophageal esophageal adenocarcinoma: a nationwide observational Turkish Oncology Group (TOG) study.
Cancers (Basel). 2024; 16(12):2251. Kutlu Y, Shute DA, Yilmaz F, et al. - Total neoadjuvant therapy versus neoadjuvant chemoradiation for locally advanced rectal cancer: a multi-institutional real-world study.
Cancers (Basel). 2024; 16( 18):3213. Senocak Tasci E, Mutlu AU, Saylik O, et al - BEGEV is an effective therapy for heavily pretreated and platinum-resistant relapsed/refractory Hodgkin’s lymphoma patients: a single-center real-life experience.
Indian J Hematol Blood Transfus. 2024 Uzay A, Tasci ES, Gundogdu Y, et al. - Efficacy of adjuvant capecitabine in residual triple-negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
Expert Opin Pharmacother. 2024:1-8. Tasci ES, Kutlu Y, Ölmez ÖF, et al - Turkish adaptation of QEQ-SH22 quality of sexual life assessment scale in cancer patients – validity and reliability study
Sisli Etfal Hastan Tip Bul. 2024;58(4):468-476. Eriş SB, Celayir OM, Tasci ES, et al. - Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).
Turkish J Med Sci. 2022;52(4): 1022-1032. Erol C, Sakin A, Basoglu T, et al.
